| 57.48 0.51 (0.9%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 71.14 | 1-year : | 83.09 |
| Resists | First : | 60.9 | Second : | 71.14 |
| Pivot price | 57.51  |
|||
| Supports | First : | 51.72 | Second : | 46.04 |
| MAs | MA(5) : | 57.2  |
MA(20) : | 55.74 |
| MA(100) : | 40.78 |
MA(250) : | 37.96 |
|
| MACD | MACD : | 2.8 |
Signal : | 3.3 |
| %K %D | K(14,3) : | 66.8 |
D(3) : | 67.6 |
| RSI | RSI(14): 59.7 |
|||
| 52-week | High : | 60.9 | Low : | 22.61 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VCYT ] has closed above bottom band by 49.6%. Bollinger Bands are 6.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 57.74 - 58.15 | 58.15 - 58.46 |
| Low: | 54.87 - 55.29 | 55.29 - 55.63 |
| Close: | 56.91 - 57.58 | 57.58 - 58.1 |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Thu, 09 Jul 2026
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 - Business Wire
Thu, 09 Jul 2026
Veracyte, Inc. Stock 12‑Month Price Target Raised to $55.8, Implies 1% Downside - TradingView
Thu, 09 Jul 2026
Does Veracyte’s (VCYT) Russell Value Index Debut Redefine Its Small-Cap Defensive Narrative? - simplywall.st
Sat, 04 Jul 2026
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction. - Yahoo Finance
Fri, 03 Jul 2026
Veracyte Inc (VCYT) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Mon, 29 Jun 2026
Price to book forward of Veracyte, Inc. – NASDAQ:VCYT - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 80 (M) |
| Shares Float | 79 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 112.6 (%) |
| Shares Short | 6,720 (K) |
| Shares Short P.Month | 7,350 (K) |
| EPS | 1.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.5 |
| Profit Margin | 16.2 % |
| Operating Margin | 16.2 % |
| Return on Assets (ttm) | 3.7 % |
| Return on Equity (ttm) | 6.9 % |
| Qtrly Rev. Growth | 21.5 % |
| Gross Profit (p.s.) | 4.95 |
| Sales Per Share | 6.78 |
| EBITDA (p.s.) | 1.3 |
| Qtrly Earnings Growth | 288.8 % |
| Operating Cash Flow | 166 (M) |
| Levered Free Cash Flow | 105 (M) |
| PE Ratio | 55.26 |
| PEG Ratio | 0 |
| Price to Book value | 3.48 |
| Price to Sales | 8.46 |
| Price to Cash Flow | 27.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|